• 

Wuxi MTLH Biotechnology Co. Ltd.

Company Introduction

• Founded in Dec. 2007 by experienced pharmaceutical researchers and professionals in the US and China;

• Initial investment of $1 M USD came from founders, government funding, and non-equity diluting grants and awards from Chinese government;

• Successfully out-licensed the China market of MTLH-001 (peptide drug) at pre-clinical stage (PDGFR antagonist) to #3 pharma in China, with upfront, milestone, and royalty payments;

• Generated multiple peptide/protein drugs against extracellular domain of receptors of proven drug target pathways (platform technology). MTLH-002 (TGF beta receptor antagonist) displayed efficacy in in vitro studies.

Business Model

Low Cost:

• China Pre-clinical and clinical development costs = 1/3-1/5 of the US cost (IND to Phase II in China around $4 M USD);

• Government non-diluting grants and awards

Fast Speed:

• With IND package generated from China, enter US Phase I faster than China;

• China clinical studies catch up by faster recruitment of patients

High Return

• Partnering with Chinese pharma companies to take advantage of growing China market (>20% per year). China market will be #2 in the world by 2020;

• At Phase II clinical proof of concept stage, license the product to a large pharma for $300-$500 M licensing fee + 20-30% royalty (cost of development: $20-40 M USD, 4-5 years)